Benitec Biopharma Inc Dossier - Source-backed chat

Benitec Biopharma Inc

BNTCNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.51

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $10.00Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $348.8M

Enterprise Value $168.9M

Shares Outstanding 34.9M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Benitec Biopharma Inc. (NASDAQ: BNTC) is a clinical-stage biotechnology company uniquely positioned as a pioneer in 'Silence and Replace' genetic medicine. Its lead candidate, BB-301, is an investigational adeno-associated virus (AAV) vector-based gene therapy targeting dysphagia in patients with Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is currently the only clinical-stage therapeutic agent in development for OPMD-related dysphagia, addressing a significant unmet medical need for approximately 15,000 patients across North America, Europe, and Israel. Recent clinical updates from its Phase 1b/2a trial demonstrate robust, durable, and deepening improvements in swallowing function at 12- and 24-months post-treatment for low-dose patients, alongside highly encouraging early dose-response signals in high-dose patients. Backed by a robust cash position of $184.8 million as of March 31, 2026, Benitec is fully capitalized to advance BB-301 through the completion of its upcoming pivotal study, significantly mitigating the existential cash-runway risks typical of micro-cap biotechs.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets5 analysts · as of 18 Aug 2026

Low · most bearish analyst$18.00

Mean target$25.80

High · most bullish analyst$32.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$10.0020%

The FDA requires a larger, longer, or more complex pivotal study design than anticipated, extending the timeline to commercialization and increasing clinical costs. Safety concerns or severe adverse events emerge as more patients are dosed with the high-dose regimen in Cohort 2. The lack of pipeline diversification leaves the company highly vulnerable to binary clinical trial risk, where any setback in BB-301 severely impacts shareholder value.

Base CaseCentral scenario

$25.8050%

Matches the consensus mean

Benitec successfully aligns with the FDA on the BB-301 pivotal study design in mid-2026 and initiates the trial. Interim clinical data in 2H-2026 continues to show durable, safe, and clinically meaningful improvements in swallowing function across both low-dose and high-dose cohorts. The company's $184.8 million cash reserve provides a comfortable runway to execute clinical milestones without immediate dilutive financing, driving steady upward valuation toward consensus analyst targets.

Bull CaseUpside scenario

$32.0030%

The upcoming FDA engagement in mid-2026 successfully formalizes a highly favorable, streamlined pivotal study design for BB-301, potentially utilizing accelerated approval pathways. Cohort 2 high-dose clinical readouts in 2H-2026 show superior, rapid, and safe disease-modifying efficacy. The company secures a lucrative global co-development or licensing partnership with a major pharmaceutical firm, validating its proprietary DNA-directed RNA interference (ddRNAi) platform and unlocking non-dilutive capital.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

First-in-class 'Silence and Replace' ddRNAi platform targeting OPMD, a rare disease with zero approved therapeutic alternatives.
Highly encouraging Phase 1b/2a interim clinical data showing durable, long-term (up to 24 months) improvements in objective and patient-reported swallowing metrics.
Strong balance sheet with $184.8 million in cash as of March 31, 2026, providing a robust runway to complete the pivotal clinical trial.
Orphan Drug and Fast Track designations from the FDA and EMA, facilitating accelerated regulatory pathways and market exclusivity.

Key Investment Risks

High pipeline concentration with extreme binary risk, as the company's valuation is almost entirely dependent on a single clinical asset (BB-301).
Regulatory execution risks surrounding the upcoming pivotal study design agreement with the FDA.
Potential long-term safety or tolerability issues associated with local surgical delivery of AAV gene therapy into the pharyngeal muscles.

Thesis Invalidation Triggers

Failure to reach an agreement with the FDA on a viable, cost-effective pivotal study design for BB-301.
Emergence of treatment-related serious adverse events (SAEs) in the high-dose Cohort 2 patients.
A material decline in swallowing efficacy or loss of durability in long-term follow-ups for Cohort 1 patients.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.